Search Advanced Search
Total result 2
    Select All
    Display Type:|
    • Hydrogen molecule enhances high density lipoprotein-mediated cholesterol efflux:from animal experiments to clinical trials

      2022, 30(11):996-1000.DOI: 10.20039/j.cnki.10073949.2022.11.012

      Keywords:hydrogen molecule high density lipoprotein cholesterol efflux animal experiment clinical trial
      Abstract (773)HTML (0)PDF 2.78 M (612)Favorites

      Abstract:Aim High density lipoprotein (HDL) has the functions of mediating reverse cholesterol transport and anti-oxidation, thereby inhibiting atherosclerosis. In the case of metabolic syndrome, diabetes, smoking, etc., HDL undergoes oxidative modification, and the activity of HDL-related enzymes decreases, resulting in weakened functions. Antioxidants such as vitamin E can reduce the oxidative modification of HDL and enhance the activity of HDL-related enzymes such as paraoxonase 1, but their long-term safety remains to be verified. Hydrogen molecule, as a novel antioxidant, plays a good role in a variety of oxidative inflammatory diseases. Our research group has been devoted to the research of hydrogen molecule and atherosclerotic cardiovascular disease, and found that hydrogen molecule can increase the plasma high density lipoprotein cholesterol level in animals and humans with metabolic syndrome and hypercholesterolemia, and enhance the activity of HDL-related enzymes and its mediated cholesterol efflux function. This article reviews the animal experiments and clinical trials of the biological effects of hydrogen molecule on HDL.

    • Losartan, Captopril and Combined Administration on the Treatment of Atherosclerotic Renal Vascular Disease

      2003, 11(4):299-303.

      Keywords:Atherosclerotic Renal Vascular Disease Animal Experiment Vascular Smooth Muscle Cell Apoptosis Losartan Captopril
      Abstract (1198)HTML (0)PDF 5.04 M (1059)Favorites

      Abstract:Aim To investigate the effects of losartan, captopril and combined administration on the atherosclerotic renal vascular disease, so as to discover the anti atherosclerotic mechanism of these two drugs. Methods Serum nitric oxide (NO), tissue plasminogen activator(t PA), inhibitor of t PA and angiotensin converting enzyme were detected by chemical method; endothelin (ET) and angiotnesin Ⅱ were detected by radioimmuno assay. The apoptosis of vascular smooth muscle cells (VSMC) was determined by cytometry technique; Expression of CD68 protein were detected by immunohistochemical method; the expression levels of MMP1 and TIMP1 mRNA were examined by reverse transcription polymerase chain reaction. Results Losartan and captopril had no influence on serum lipid, creatine and BUN. Losartan alone and combined use with captopril could lower blood pressure significantly. The degree of renal and aortic atherosclerosis had good correlation. Compared with cholesterol diet group, losartan and combined drug administration group had smaller renal intimal area ratio (p<0.05), lower cholesterol contents in the renal atherosclerotic plaque (p<0.05), higher apoptosis percentage of VSMC (p<0.01) and lower levels of the expressions of CD68 protein (p<0.05) and MMP1 mRNA. Losartan may also elevate serum content of t PA(p<0.05). Conclusions Losartan and captopril can influence the pathogenesis of renal atherosclerosis by lowering blood pressure, enhancing apoptosis of VSMC, improving endothelial function, increasing fibrolysic function and stabilizing atherosclerotic plaque.

    Prev1Next
    Page 1 Result 2 Jump toPageGO
Year of publication